Olema Pharmaceuticals, Inc. (OLMA) Earnings Call Transcripts

Olema Pharmaceuticals, Inc.'s Latest Earnings Call - June 9, 2026

In the Q2 2026 earnings call for Olema Pharmaceuticals, the company reiterated its commitment to advancing treatments for ER-positive/HER2-negative breast cancer, with a focus on its lead asset, palazestrant. The CEO highlighted that the company has approximately $505 million in cash, which is expected to fund operations into the second half of 2028. The upcoming OPERA-01 trial readout in the fall is a critical event, as it will provide top-line data that could significantly impact the stock's trajectory. Management maintained a positive outlook on ongoing clinical trials, particularly for the KAT6/7 inhibitor, which has shown promising monotherapy activity in preliminary data.

Reported metrics

Guidance from management

Management is optimistic about the upcoming OPERA-01 trial readout and is exploring combination therapies involving KAT6. No changes to guidance were explicitly mentioned, but the focus remains on executing ongoing trials effectively.

What management said

Yes. So at the end of Q1, we had about $505 million, just a little worth of $0.5 billion on our balance sheet. That will take us nicely into the second half of 2028. And that is with the execution of OPERA-01, continued execution of OPERA-02, our first-line trial with Kisqali in breast cancer, certainly the remainder of the Phase I/II for OP-3136 and also our efforts to file assuming OPERA-01 is positive on palazestr...

The optimistic as we might be able to have some, particularly from fulvestrant. Fulvestrant is only one dose level behind monotherapy by the end of the year, certainly first half of next year.

What analysts pressed on

Analysts expressed concerns about the negative results from the persevERA trial and its implications for OPERA-02. There is also apprehension regarding the competitive landscape and the efficacy of Olema's treatments compared to emerging therapies.

Main topics on the call

• Upcoming OPERA-01 Readout — Olema is set to release top-line data from the OPERA-01 trial in the fall of 2026. CEO Sean Bohen stated, "We're reiterating the top line data in the fall," which is crucial for the company's future prospects.
• Cash Position and Runway — The company reported a cash position of approximately $505 million, which is expected to sustain operations through the second half of 2028. This strong cash position supports ongoing trials and potential commercializati...
• KAT6/7 Inhibitor Progress — The KAT6/7 inhibitor has demonstrated single-agent antitumor activity in both ER-positive/HER2-negative breast cancer and castration-resistant prostate cancer. Management noted, "We saw single-agent antitumor activity in...
• Concerns from PersevERA Trial — The recent persevERA trial did not achieve statistical significance, raising concerns about the efficacy of similar treatments. Bohen acknowledged, "The trial was negative... but there's very clear evidence of activity,"...

Read the full Olema Pharmaceuticals, Inc. transcript (June 9, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 6 Olema Pharmaceuticals, Inc. earnings call transcripts on record, spanning November 29, 2023 to June 9, 2026. Based on this history, Olema Pharmaceuticals, Inc. reports semi-annually. The most recent call on file is dated June 9, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

OLMA

Exchange

NasdaqGS

Country

US

Sector

Health Care

Industry

Biotechnology

Calls on record

6

First call

November 29, 2023

Most recent

June 9, 2026

Reporting cadence

semi-annually